# Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

> **NCT07444398** · PHASE1 · RECRUITING · sponsor: **Khawaja Danish Ali** · enrollment: 130 (estimated)

## Conditions studied

- Decompensated Heart Failure

## Interventions

- **DRUG:** Vericiguat tablet
- **DRUG:** Sacubitril / Valsartan

## Key facts

- **NCT ID:** NCT07444398
- **Lead sponsor:** Khawaja Danish Ali
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444398, "Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07444398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*